

8. (Twice Amended) An isolated polypeptide that exhibits a TANGO 294 activity and is selected from the group consisting of:

a) a fragment of a polypeptide which has an amino acid sequence comprising any one of SEQ ID NOs: 47, 49, and the amino acid sequence encoded by clone EpT294, which was deposited as ATCC[®] Accession Number 207220, wherein the fragment comprises at least 40 contiguous amino acid residues of either SEQ ID NO: 47 or the amino acid sequence encoded by clone EpT294;

Rule C1
b) a variant of a polypeptide that has an amino acid sequence comprising any one of SEQ ID NOs: 47, 49, and the amino acid sequence encoded by clone EpT294, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule having the nucleotide sequence of any one of SEQ ID NOs: 45, 46, and clone EpT294, or a complement thereof under stringent conditions, wherein the stringent conditions comprise hybridization in 6 × sodium chloride/sodium citrate buffer (SSC) at 45°C, followed by washing in 0.2 × SSC comprising 0.1% SDS at 65°C; and
B1

c) a polypeptide which is encoded by a nucleotide sequence having a portion which is at least 90% identical to any one of SEQ ID NOs: 45, 46, and the nucleotide sequence of clone EpT294.

9. (Twice Amended) The isolated polypeptide of claim 8, having the amino acid sequence of any one of SEQ ID NOs: 47, 49, and the amino acid sequence encoded by clone EpT294.

B2
24. (Amended) The isolated polypeptide of claim 8,

wherein the isolated polypeptide is a fragment of a polypeptide which has an amino acid sequence comprising any one of SEQ ID NOs: 47, 49, and the amino acid sequence encoded by clone EpT294, and

wherein the sequence of the fragment comprises at least 40 contiguous amino acid residues of SEQ ID NO: 47.

B2
Cont
25. (Amended) The isolated polypeptide of claim 24, wherein the sequence of the fragment comprises at least 75 contiguous amino acid residues of SEQ ID NO: 47.

26. (Amended) The isolated polypeptide of claim 24, wherein the sequence of the fragment comprises at least 150 contiguous amino acid residues of SEQ ID NO: 47.

28. (Amended) The isolated polypeptide of claim 8, wherein the TANGO 294 activity is selected from the group consisting of

- B3
- i) ability to modulate absorption of a lipid;
 - ii) ability to modulate metabolism of a lipid;
 - iii) ability to modulate transport of a lipid; and
 - iv) lipase activity.

30. (Amended) The isolated polypeptide of claim 8,

wherein the isolated polypeptide is a variant of a polypeptide that has an amino acid sequence comprising any one of SEQ ID NOs: 47, 49, and the amino acid sequence encoded by clone EpT294, and

wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule having the nucleotide sequence of any one of SEQ ID NOs: 45, 46, and clone EpT294, or a complement thereof, under stringent conditions, wherein the stringent

24 C2/34 Cont
conditions comprise hybridization in 6 × sodium chloride/sodium citrate buffer (SSC) at 45°C, followed by washing in 0.2 × SSC comprising 0.1% SDS at 65°C.

35. (Amended) The isolated polypeptide of claim 8, wherein the isolated
B5 polypeptide is encoded by a nucleotide sequence having a portion which is at least 90% identical to any one of SEQ ID NOs: 45, 46, and the nucleotide sequence of clone EpT294.

Please add claim 47 as follows.

-- 47. The isolated polypeptide of claim 28, wherein the TANGO 294 activity is
B6 lipase activity. --

REMARKS

Claims 8-10, 24-26, 28-30, 33-36, and 38-47 are pending in the present application following entry of this Amendment. Claims 27, 31, 32, and 37 have been cancelled without prejudice. Claims 8, 9, 24-26, 28, 30, and 35 have been amended. Claim 47 has been added. Claims 8, 42, and 46 are the only independent claims.

No new matter is added by the amendments. Support for the amendments to each of the claims is found in the specification at least at page 87, lines 21-24 and the claims as originally filed. The pending claims have been amended to exclude the sequences considered by the Examiner in Paper No. 10 to be withdrawn from consideration, namely SEQ ID NOs: 48 and 50-52. Identity of clone EpT294 with the clone deposited as ATCC[®] 207220 is disclosed in the specification, for example at page 160, line 28, through page 161, line 29.

I. Oath or Declaration.

At page 2 of Paper No. 10, the Examiner has asserted that the Oath filed with this application is defective, because the inventors "did not sign their name in full." The Applicants submit herewith a Declaration and Power of Attorney executed in full by each individual inventor. Accordingly, it is submitted that the Examiner's objection is no longer applicable. Withdrawal of the objection is requested.